Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$17.62
-$2.34(-11.71%)
At close: 4:00 PM EDT
$17.62
-$2.34(-11.71%)
Day’s Range― - ―
52-Week Range$9.82 - $21.45
Previous CloseN/A
Volume3.88M
Average Volume (3M)1.18M
Market Cap
$1.81B
Enterprise Value$1.54K
Total Cash (Recent Filing)$440.56M
Total Debt (Recent Filing)$233.42M
Price to Earnings (P/E)―
Beta1.39
Next Earnings
Oct 22, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding116,445,840
10 Day Avg. Volume846,043
30 Day Avg. Volume1,182,174
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.50Price Target Upside67.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.25
Revenue Forecast (FY)$725.81M
Bulls Say, Bears Say
Bulls Say
Revenue And Patient GrowthGrowth in revenue and active patients indicates expanding utilization of NovoCure’s recurring therapy model. Continued adoption of Optune Gio supports a larger installed patient base, while the updated 2026 revenue guidance suggests management expects commercial momentum to persist.
Pipeline And Product ExpansionRegulatory approval for Optune Pax expands NovoCure’s addressable market beyond existing indications and provides a durable growth avenue in pancreatic cancer. The supporting clinical results and planned German rollout strengthen the platform’s commercial and competitive position.
Improving Margins And Operating DisciplineThe combination of high gross margins, positive adjusted EBITDA, and lower operating expenses shows improving operating leverage. If sustained, these trends can shorten the path to management’s targeted 2026 adjusted EBITDA breakeven while preserving resources for launches and clinical development.
Bears Say
Persistent Losses And Cash BurnNovoCure has not yet demonstrated sustainable GAAP profitability or positive free cash flow, despite improved quarterly results. Continued losses and cash burn could reduce financial flexibility over time and increase dependence on revenue growth and expense control to fund operations.
Reimbursement And Contracting BarriersMarket access requirements can slow patient onboarding even when regulatory approval or national reimbursement exists. Hospital-level contracting in Japan and country-specific EU constraints may therefore delay adoption, limit near-term scale, and increase the execution burden for commercial expansion.
Clinical And Adoption Execution RiskThe company must convert initial Optune Pax prescriptions into repeat use to establish durable demand, while changes to LUNAR-2 could affect evidence generation. Weak repeat adoption or less robust trial execution would limit expansion of the TTFields platform.
NovoCure News
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $9.82 and its highest was $21.45 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $1.81B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Oct 22, 2026 which is in 39 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Jul 23, 2026. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.332 by $0.202.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.25.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 116,445,840 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.332. Following the earnings report the stock price went up 28.388%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.50 (67.42% Upside)
$29.50 (67.42% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 86%
Sector Average 62%
Sector Average 62%
Hedge Fund Trend
Decreased
By 38.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.17%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Company Deck
NVCR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial commercial momentum highlighted by record net revenue (+16% YoY), active patient growth (Optune Gio +11% YoY), successful early launches (Optune Pax and Optune Lua), and a return to positive adjusted EBITDA in the quarter. Management also emphasized disciplined cost-management actions (R&D reductions and LUNAR-2 optimization) and updated full-year guidance reflecting confidence in continued progress. Key challenges include reimbursement and contracting hurdles (EU and Japan), reliance on some one-time benefits in Q2, the need to convert one-time prescribers into repeat prescribers for sustained growth, and clinical trial redesign risks. Overall, the positives — stronger commercial performance, profitability trajectory, regulatory milestones and clear launch progress — meaningfully outweigh the identified lowlights.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$29.50
▲(67.42% Upside)
Technical Analysis
Ownership Overview
2.72% Insiders
22.46% Mutual Funds
17.06% Other Institutional Investors
40.91% Public Companies and
Individual Investors